Intellia Therapeutics (NTLA) Non-Current Deffered Revenue (2015 - 2025)

Intellia Therapeutics (NTLA) has 11 years of Non-Current Deffered Revenue data on file, last reported at $12.5 million in Q3 2025.

• On a quarterly basis, Non-Current Deffered Revenue fell 44.53% year-over-year to $12.5 million in Q3 2025; TTM through Sep 2025 was $12.5 million, a 44.53% decrease from a year earlier, with the FY2024 full-year figure at $18.3 million, down 53.01% from the prior year.
• Non-Current Deffered Revenue for Q3 2025 stood at $12.5 million, roughly flat from $12.5 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for NTLA reached as high as $63.5 million in Q4 2021 and fell as low as $12.5 million in Q2 2025.
• Historically, Non-Current Deffered Revenue has averaged $29.6 million across 5 years, with a median of $25.7 million in 2022.
• Across the five-year window, Non-Current Deffered Revenue soared 251.99% in 2021 and sank 71.99% in 2023, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $63.5 million in 2021, then slumped by 68.6% to $19.9 million in 2022, then surged by 94.93% to $38.9 million in 2023, then tumbled by 53.01% to $18.3 million in 2024, then slumped by 31.32% to $12.5 million in 2025.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $12.5 million in Q3 2025, $12.5 million in Q2 2025, and $13.2 million in Q1 2025.